Advertisement

Canadian Journal of Public Health

, Volume 104, Issue 1, pp e33–e38 | Cite as

Poorer Physical Health-related Quality of Life Among Aboriginals and Injection Drug Users Treated With Highly Active Antiretroviral Therapy

  • Leah J. MartinEmail author
  • Stan Houston
  • Yutaka Yasui
  • T. Cameron Wild
  • L. Duncan Saunders
Quantitative Research

Abstract

OBJECTIVE: We compared the health-related quality of life (HRQL) of Aboriginal and non-Aboriginal HIV patients after they started highly active antiretroviral therapy (HAART) in Edmonton, Alberta and investigated whether clinical status (CD4 cell count and viral load) might explain any observed differences.

METHODS: In 2006–2007, eligible patients who started HAART in 1997–2005 completed the MOS-HIV to measure HRQL. Using multiple linear regression models, we compared physical (PHS) and mental (MHS) health summary scores across four groups: Aboriginals infected with HIV via injection drug use (AB/IDUs); Aboriginal non-IDUs (AB/non-IDUs); non-Aboriginal IDUs (non-AB/IDUs); and non-Aboriginal non-IDUs (non-AB/non-IDUs). To assess whether clinical status could explain any observed group differences, we fitted a model adjusting for socio-demographics (age and sex) and years since starting HAART only and then additionally adjusted for current clinical status.

RESULTS: Ninety-six patients were eligible (35% Aboriginal, 42% IDU). Adjusting for socio-demographics and years since starting HAART, AB/IDUs (p=0.008), AB/non-IDUs (p=0.002), and non-AB/IDUs (p=0.002) had lower PHS scores than non-AB/non-IDUs. After additionally adjusting for clinical status, these relationships remained significant for AB/non-IDUs (p=0.027) and non-AB/IDUs (p=0.048) but not for AB/IDUs (p=0.12). AB/IDUs and non-AB/IDUs tended to have worse MHS scores than non-AB/non-IDUs, but these relationships were not statistically significant and weakened after adjusting for current clinical status.

CONCLUSIONS: AB/IDU, AB/non-IDUs, and non-AB/IDUs had significantly poorer physical HRQL than non-AB/non-IDUs. These differences appear to be partially explained by poorer clinical status, especially for AB/IDUs, which suggests that observed inequalities in physical HRQL may be diminished by improving patients’ clinical status; for example, through improved adherence to HAART.

Key words

Aboriginal populations antiretroviral therapy, highly active intravenous drug users treatment outcomes health-related quality of life 

Résumé

OBJECTIF: Nous avons comparé la qualité de vie liée à la santé (QVLS) de patients autochtones et non autochtones atteints du VIH après le début d’une thérapie antirétrovirale hautement active (TAHA) à Edmonton (Alberta) et cherché à savoir si leur état clinique (numération des lymphocytes CD4 et charge virale) pouvait expliquer les différences observées.

MÉTHODE: En 2006–2007, des patients admissibles ayant entamé une TAHA en 1997–2005 ont rempli le questionnaire MOS-HIV, qui mesure la QVLS. À l’aide de modèles de régression linéaire multiple, nous avons comparé les cotes sommaires de santé physique (CSP) et de santé mentale (CSM) de quatre groupes: les Autochtones infectés par le VIH via l’utilisation de drogues par injection (Aut./UDI); les Autochtones non-UDI (Aut./non-UDI); les non-Autochtones UDI (non-Aut./UDI); et les non-Autochtones non-UDI (non-Aut./non-UDI). Pour déterminer si l’état clinique pouvait expliquer les différences observées entre ces groupes, nous avons adapté un modèle en tenant compte des caractéristiques sociodémographiques (âge et sexe) et du nombre d’années depuis le début de la TAHA seulement, puis en tenant compte, en plus, de l’état clinique actuel.

RÉSULTATS: Quatre-vingt-seize patients étaient admissibles (35 % d’Autochtones, 42 % d’UDI). Compte tenu des caractéristiques sociodémographiques et du nombre d’années depuis le début de la TAHA, les Aut./UDI (p=0,008), les Aut./non-UDI (p=0,002) et les non-Aut./UDI (p=0,002) avaient des cotes CSP inférieures à celles des non-Aut./non-UDI. En tenant aussi compte de l’état clinique, ces relations demeuraient significatives pour les Aut./non-UDI (p=0,027) et les non-Aut./UDI (p=0,048), mais pas pour les Aut./UDI (p=0,12). Les Aut./UDI et les non-Aut./UDI avaient tendance à présenter des CSM inférieures à celles des non-Aut./non-UDI, mais ces relations n’étaient pas significatives, et elles s’affaiblissaient après la prise en considération de l’état clinique actuel.

CONCLUSION: La QVLS physique des Aut./UDI, des Aut./non-UDI et des non-Aut./UDI était significativement inférieure à celle des non-Aut./non-UDI. Ces différences semblent s’expliquer en partie par un moins bon état clinique, surtout pour les Aut./UDI, ce qui laisse entendre que les inégalités observées dans la QVLS physique peuvent être réduites si l’on améliore l’état clinique des patients, par exemple en améliorant l’observance de la TAHA.

Mots clés

populations autochtones thérapie antirétrovirale hautement active toxicomanie intraveineuse résultat thérapeutique qualité de vie liée à la santé 

References

  1. 1.
    Martin LJ, Houston S, Yasui Y, Wild TC, Saunders LD. Rates of initial virolog-ical suppression and subsequent virological failure after initiating highly active antiretroviral therapy: The impact of Aboriginal ethnicity and injection drug use. Curr HIV Res 2010;8(8):649–58.CrossRefGoogle Scholar
  2. 2.
    Martin LJ, Houston S, Yasui Y, Wild TC, Saunders LD. All-cause and HIV-related mortality rates among HIV-infected patients after initiating highly active anti-retroviral therapy: The impact of Aboriginal ethnicity and injection drug use. Can J Public Health 2011;102(2):90–96.PubMedGoogle Scholar
  3. 3.
    Lima VD, Kretz P, Palepu A, Bonner S, Kerr T, Moore D, et al. Aboriginal status is a prognostic factor for mortality among antiretroviral naïve HIVpositive individuals first initiating HAART. AIDS Res Ther 2006;3:14.CrossRefGoogle Scholar
  4. 4.
    Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR Recomm Rep 2002;51(RR-7):1–55.PubMedGoogle Scholar
  5. 5.
    Brandson EK, Fernandes KA, Palmer A, Clement K, Olson B, Lima VD, et al. HAART-full of life: Variations in quality of life among Aboriginal and non-Aboriginal peoples ever on antiretroviral therapy in BC. XVII International AIDS Conference. 2008 Aug 3-8; Mexico City, Mexico. Abstract no. THPE0818. Available at: http://www.iasociety.org/Default.aspx?pageId=11&abstractId=200718980 (Accessed March 6, 2012).
  6. 6.
    Call SA, Klapow JC, Stewart KE, Westfall AO, Mallinger AP, Demasi RA, et al. Health-related quality of life and virologic outcomes in an HIV clinic. Qual Life Res 2000;9(9):977–85.CrossRefGoogle Scholar
  7. 7.
    Préau M, Protopopescu C, Spire B, Sobel A, Dellamonica P, Moatti J P, et al. Health related quality of life among both current and former injection drug users who are HIV-infected. Drug Alcohol Depend 2007;86(2-3):175–82.CrossRefGoogle Scholar
  8. 8.
    Burgoyne RW, Saunders DS. Quality of life among urban Canadian HIV/AIDS clinic outpatients. Int J STD AIDS 2001;12(8):505–12.CrossRefGoogle Scholar
  9. 9.
    Badia X, Podzamczer D, Garcia M, Lopez-Lavid CC, Consiglio E. A randomized study comparing instruments for measuring health-related quality of life in HIV-infected patients. AIDS 1999;13(13):1727–35.CrossRefGoogle Scholar
  10. 10.
    Public Health Agency of Canada. HIV/AIDS Epi Updates, November 2007. Ottawa, ON: Centre for Infectious Disease Prevention and Control. Surveillance and Risk Assessment Division, PHAC, 2007.Google Scholar
  11. 11.
    Dalgard O, Egeland A, Skaug K, Vilimas K, Steen T. Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection. Hepatology 2004;39(1):74–80.CrossRefGoogle Scholar
  12. 12.
    Perez IR, Bano JR, Lopez Ruz MA, Jiminez AA, Prados MC, Liano JP, et al. Health-related quality of life of patients with HIV: Impact of sociodemo-graphic, clinical and psychosocial factors. Qual Life Res 2005;14:1301–10.CrossRefGoogle Scholar
  13. 13.
    Wu AW, Revicki DA, Jacobson D, Malitz FE. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res 1997;6(6):481–93.CrossRefGoogle Scholar
  14. 14.
    Public Health Agency of Canada. HIV and AIDS in Canada. Surveillance Report to December 31, 2006. Ottawa: Centre for Infectious Disease Prevention and Control, Surveillance and Risk Assessment Division, PHAC, 2007.Google Scholar
  15. 15.
    Wu AW. MOS-HIV Health Survey Scoring Guidelines. Waltham, MA: Medical Outcomes Trust, 1997.Google Scholar
  16. 16.
    Dohoo I, Martin W, Stryhn H. Veterinary Epidemiologic Research, 2nd ed. Charlottetown, PE: VER Inc., 2009.Google Scholar
  17. 17.
    Clarke DE, Colantonio A, Rhodes AE, Escobar M. Pathways to suicidality across ethnic groups in Canadian adults: The possible role of social stress. Psychol Med 2008;38(3):419–31.CrossRefGoogle Scholar
  18. 18.
    Rosenbloom MJ, Sullivan EV, Sassoon SA, O’Reilly A, Fama R, Kemper CA, et al. Alcoholism, HIV infection, and their comorbidity: Factors affecting self-rated health-related quality of life. J Stud Alcohol Drugs 2007;68(1):115–25.CrossRefGoogle Scholar
  19. 19.
    Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988.Google Scholar

Copyright information

© The Canadian Public Health Association 2012

Authors and Affiliations

  • Leah J. Martin
    • 1
    Email author
  • Stan Houston
    • 1
    • 2
  • Yutaka Yasui
    • 1
  • T. Cameron Wild
    • 3
  • L. Duncan Saunders
    • 1
  1. 1.School of Public HealthUniversity of AlbertaEdmontonCanada
  2. 2.Division of Infectious Diseases, Department of MedicineUniversity of AlbertaEdmontonCanada
  3. 3.Centre for Health Promotion Studies, School of Public HealthUniversity of AlbertaEdmontonCanada

Personalised recommendations